Amivan

Amivan

ramipril

Manufacturer:

ACME

Distributor:

Bell-Kenz Pharma

Marketer:

Euro Generics
Concise Prescribing Info
Contents
Ramipril
Indications/Uses
Mild to severe HTN, alone or in combination w/ thiazide diuretics. CHF. Reduces risk of stroke, MI & death from CV events in patients w/ history of CV disease.
Dosage/Direction for Use
HTN Adult Initially 1.25-2.5 mg once daily, adjusted at 2-wk intervals. Maintenance dose: 2.5-20 mg as single or in 2 divided doses daily, if BP is not controlled w/ Ramipril alone, diuretic may be added. CHF after MI Initiate as early as 2 days after MI. Initially 2.5 mg bid, may be reduced to 1.25 mg bid if hypotension occurs. Titrate to 5 mg bid w/ dosage increasing about 3 wk apart. Prevention of major CV events 2.5 mg once daily for the 1st wk of therapy & 5 mg once daily the following wk then may be increased as tolerated. Maintenance dose: 10 mg once daily. Patient w/ HTN & renal impairment Initially 1.25 mg once daily. Max: 5 mg daily. Patient w/ heart failure & renal impairment 1.25 mg once daily, may be increased to 1.25 mg bid. Max: 2.5 mg bid.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. History of angioedema related to previous treatment w/ ACE inhibitor.
Special Precautions
Anaphylactoid & possibly related reactions, head & neck angioedema, intestinal angioedema, hypotension, hepatic failure, neutropenia/agranulocytosis, hematological reactions in patients w/ collagen vascular disease (eg, SLE, scleroderma) & renal impairment. Monitor WBC in patients w/ collagen vascular disease. Hyperkalemia, hypotension. Cough. Patients undergoing surgery or during anesth. Impaired renal/liver function. Pregnancy. Elderly.
Adverse Reactions
Anaphylactoid reactions; symptomatic hypotension, syncope, palpitations; cough; pancytopenia, hemolytic anemia, thrombocytopenia; increase in BUN & serum creatinine, acute renal failure; angioneurotic edema; hepatic failure, hepatitis, jaundice, pancreatitis, abdominal pain, anorexia, constipation, diarrhea, dry mouth, dyspepsia, dysphagia, gastroenteritis, increased salivation & taste disturbance, nausea & vomiting; apparent hypersensitivity reactions (manifested by urticarial, pruritus, or rash, w/ or w/o fever), photosensitivity, purpura, onycholysis, pemphigus, pemphigoid, erythema multiforme, toxic epidermal necrolysis & Stevens-Johnson syndrome; anxiety, amnesia, convulsions, depression, hearing loss, insomnia, nervousness, neuralgia, neuropathy, paresthesia, somnolence, tinnitus, tremor, vertigo & vision disturbances, dizziness, headache; positive ANA, elevated erythrocyte sedimentation rate, arthralgia/arthritis, fever, vasculitis, eosinophilia, rash & other dermatologic manifestations; dyspnea, edema, epistaxis, impotence, increased sweating, malaise, myalgia, wt gain.
Drug Interactions
Serious hypotension & hyperkalemia w/ K-sparing diuretics. May increase lithium conc. Reduced antihypertensive effects & deterioration of renal function w/ NSAIDs.
ATC Classification
C09AA05 - ramipril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Amivan FC tab 5 mg
Packing/Price
30's (P405/film-coated tab)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in